Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 17/05/2024 BST 5-day change 1st Jan Change
109 USD -1.36% Intraday chart for Jazz Pharmaceuticals plc -0.58% -11.39%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
US reclassification could drive fresh research funding into pot sector RE
Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing MT
UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating MT
Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook MT
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $18.15 - $19.35 MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q1 Revenue $902M, vs. Street Est of $954.3M MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q1 EPS $2.68, vs. Street Est of $4.18 MT
Transcript : Jazz Pharmaceuticals plc, Q1 2024 Earnings Call, May 01, 2024
Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024 CI
Jazz Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment MT
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer CI
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating MT
Transcript : Jazz Pharmaceuticals plc - Special Call
Stifel Raises Jazz Pharmaceuticals' Price Target to $230 From $225, Maintains Buy Rating MT
H.C. Wainwright Cuts Price Target on Jazz Pharmaceuticals to $200 From $204, Maintains Buy Rating MT
Transcript : Jazz Pharmaceuticals plc Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 02:00 PM
Transcript : Jazz Pharmaceuticals plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 10:30 AM
UBS Adjusts Jazz Pharmaceuticals Price Target to $131 From $135, Maintains Neutral Rating MT
Barclays Cuts Price Target on Jazz Pharmaceuticals to $230 From $235, Maintains Overweight Rating MT
Needham Cuts Price Target on Jazz Pharmaceuticals to $220 From $225, Maintains Buy Rating MT
Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on November 8, 2016. CI
Jazz Pharmaceuticals Swings to Q4 Non-GAAP Earnings, Revenue Rises; 2024 Guidance Set, Shares Down After Hours MT
Transcript : Jazz Pharmaceuticals plc, Q4 2023 Earnings Call, Feb 28, 2024
Chart Jazz Pharmaceuticals plc
More charts
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
109 USD
Average target price
182 USD
Spread / Average Target
+66.99%
Consensus
  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. News Jazz Pharmaceuticals plc
  5. Jazz Pharmaceuticals to Acquire Redx Pharma's KRAS Inhibitor Program